Table 2.

Glycemic parameters before and after SGLT2i administration.

	Before SGLT2i initiation	12 months after SGLT2i initiation	P (change adjusted for baseline; baseline vs 12 months)
HbA1c (%) [mmol/mol] (N=11)	9.2±2.0 [77.6±21.2]	8.4±1.8 [67.9±19.6]	0.028
HbA1c (%) adjusted for % change in insulin dose	N/A	N/A	0.029
Total daily dose of insulin (units) (N=12)	161±179	119±134	0.17
Fasting plasma glucose (mg/dL) (N=9)	177±91	158±50	0.62
24-hour urine glucose excretion (g/24hrs) (N=2)	13.3±2.1	70.0±15.8	0.062
Fasting C-peptide (ng/ml) (N=5)	6.1 (4.2,10.8)	3.4 (2.8, 6.3)	0.071
Triglycerides (mg/dL) (N=10)	332 (113, 744)	181 (150, 1189)	0.99
Total cholesterol (mg/dL) (N=10)	150±37	165±40	0.25
LDL-C (mg/dL) (N=7)	68±35	90±36	0.26
HDL-C (mg/dL) (N=9)	30±7	31±7	0.40
eGFR (mL/min/1.73m2) (N=10)	105±24	104±34	0.72
Systolic blood pressure (mmHg) (N=6)	129±11	116±12	0.011
Diastolic blood pressure (mmHg) (N=6)	77±8	67±10	0.013

N/A, not applicable; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; eGFR, estimated glomerular filtration rate